SCHEMBL205709

SCHEMBL205709

COc1ccc(Nc2nc(-c3ccccc3)c(-c3ccccc3)s2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.78
ALDH1A1 P00352 9/20 0.78
GAA P10253 9/20 0.78
MEN1 O00255 8/20 0.78
KMT2A Q03164 8/20 0.78
KDM4E B2RXH2 5/20 0.78
SMN1; SMN2 Q16637 5/20 0.78
RAB9A P51151 5/20 0.78
NPC1 O15118 4/20 0.78
HTT P42858 2/20 0.78
HPGD P15428 1/20 0.78
NPSR1 Q6W5P4 1/20 0.78
PTGDR2 Q9Y5Y4 2/20 0.66
DHODH Q02127 1/20 0.63
NFKB1 P19838 4/20 0.59
NFKB2 Q00653 4/20 0.59
RELA Q04206 4/20 0.59
RECQL P46063 2/20 0.59
ALOX5 P09917 2/20 0.59
POLB P06746 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281996 0.88 MAPT (0.62) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL18904279 0.87 MAPT (0.67) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL10686112 0.86 MEN1 (0.68) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL208098 0.86 MAPT (0.63) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL12174566 0.86 PTGDR2 (0.63) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL4057621 0.85 ALDH1A1 (0.66) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL4393456 0.84 DHODH (0.75) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL12158063 0.83 PTGDR2 (0.77) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL206405 0.81 MEN1 (0.54) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL1302256 0.81 PTGS2 (0.67) MAPTALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 MAPT 2207/4885ALDH1A1 109/4885GAA 1359/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 MAPT 2207/4885ALDH1A1 109/4885GAA 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.